These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17854307)

  • 1. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
    Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Chauhan D; Munshi NC; Richardson PG; Anderson KC
    Br J Haematol; 2007 Oct; 139(1):55-63. PubMed ID: 17854307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
    Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
    Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
    Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
    Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cafestol has a weaker inhibitory effect on osteoclastogenesis than kahweol and promotes osteoblast differentiation.
    Fukuma Y; Sakai E; Nishishita K; Okamoto K; Tsukuba T
    Biofactors; 2015; 41(4):222-31. PubMed ID: 26154488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
    Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.
    Han JH; Choi SJ; Kurihara N; Koide M; Oba Y; Roodman GD
    Blood; 2001 Jun; 97(11):3349-53. PubMed ID: 11369623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood mononuclear phagocytes from patients with chronic periodontitis are primed for osteoclast formation.
    Herrera BS; Bastos AS; Coimbra LS; Teixeira SA; Rossa C; Van Dyke TE; Muscara MN; Spolidorio LC
    J Periodontol; 2014 Apr; 85(4):e72-81. PubMed ID: 24059638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
    Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
    J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
    Rossi M; Pitari MR; Amodio N; Di Martino MT; Conforti F; Leone E; Botta C; Paolino FM; Del Giudice T; Iuliano E; Caraglia M; Ferrarini M; Giordano A; Tagliaferri P; Tassone P
    J Cell Physiol; 2013 Jul; 228(7):1506-15. PubMed ID: 23254643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK5 activation is essential for osteoclast differentiation.
    Amano S; Chang YT; Fukui Y
    PLoS One; 2015; 10(4):e0125054. PubMed ID: 25885811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human osteoclast-like cells are formed from peripheral blood mononuclear cells in a coculture with SaOS-2 cells transfected with the parathyroid hormone (PTH)/PTH-related protein receptor gene.
    Matsuzaki K; Katayama K; Takahashi Y; Nakamura I; Udagawa N; Tsurukai T; Nishinakamura R; Toyama Y; Yabe Y; Hori M; Takahashi N; Suda T
    Endocrinology; 1999 Feb; 140(2):925-32. PubMed ID: 9927325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation.
    Vanhara P; Lincová E; Kozubík A; Jurdic P; Soucek K; Smarda J
    Differentiation; 2009 Nov; 78(4):213-22. PubMed ID: 19695766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo.
    Ishizuka H; García-Palacios V; Lu G; Subler MA; Zhang H; Boykin CS; Choi SJ; Zhao L; Patrene K; Galson DL; Blair HC; Hadi TM; Windle JJ; Kurihara N; Roodman GD
    J Bone Miner Res; 2011 Jan; 26(1):169-81. PubMed ID: 20683884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.
    Shanmugarajan S; Youssef RF; Pati P; Ries WL; Rao DS; Reddy SV
    J Cell Biochem; 2008 Jul; 104(4):1500-8. PubMed ID: 18348201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.